Simultaneous determination of sibutramine and its active metabolites in human plasma by LC-MS/MS and its application to a pharmacokinetic study

Biomedical Chromatography

Volumn 25, Issue 11, 2011, Pages 1181-1188

  Bae, Jung Woo ^a   Choi, Chang Ik ^a   Jang, Choon Gon ^a   Lee, Seok Yong ^a  

^a Sungkyunkwan University   (South Korea)

Author keywords

LC MS MS; N di desmethyl sibutramine; N mono desmethyl sibutramine; Pharmacokinetics; Sibutramine

Indexed keywords

BIOMOLECULES; ELECTROSPRAY IONIZATION; LIQUID CHROMATOGRAPHY; MASS SPECTROMETRY; METABOLITES; PLASMA (HUMAN); POSITIVE IONS;

ACTIVE METABOLITES; HUMAN PLASMAS; LC-MS-MS; LC.MS/MS; MOBILE PHASIS; N-DI-DESMETHYL SIBUTRAMINE; N-MONO-DESMETHYL SIBUTRAMINE; PHARMACOKINETIC STUDIES; SIBUTRAMINE; SIMULTANEOUS DETERMINATIONS;

PHARMACOKINETICS;

CHLORPHENIRAMINE; DRUG METABOLITE; N NORSIBUTRAMINE; SIBUTRAMINE; UNCLASSIFIED DRUG; CYCLOBUTANE DERIVATIVE;

ACCURACY; ADULT; ARTICLE; CALIBRATION; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG ISOLATION; ELECTROSPRAY MASS SPECTROMETRY; FLOW RATE; HUMAN; HUMAN EXPERIMENT; LIQUID CHROMATOGRAPHY; MALE; NORMAL HUMAN; QUANTITATIVE ANALYSIS; REVERSED PHASE LIQUID CHROMATOGRAPHY; VALIDATION PROCESS; BLOOD; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; PROCEDURES; REPRODUCIBILITY; SENSITIVITY AND SPECIFICITY; STATISTICAL MODEL; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

ADULT; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYCLOBUTANES; HUMANS; LINEAR MODELS; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; TANDEM MASS SPECTROMETRY; YOUNG ADULT;

EID: 80053605705     PISSN: 02693879     EISSN: 10990801     Source Type: Journal    
DOI: 10.1002/bmc.1587     Document Type: Article

References (18)

1. Abolfathi Z, Couture J, Vallée F, LeBel M, Tanguay M and Masson E. A pilot study to evaluate the pharmacokinetics of sibutramine in healthy subjects under fasting and fed conditions. Journal of Pharmacy and Pharmacological Science 2004; 7: 345-349.
2. Bae SK, Cao S, Seo KA, Kim H, Kim MJ, Shon JH, Liu KH, Zhou HH and Shin JG. Cytochrome P450 2B6 catalyzes the formation of pharmacologically active sibutramine (N-{1-[1-(4-chlorophenyl)cyclobutyl]-3-methylbutyl}-N, N-dimethylamine) metabolites in human liver microsomes. Drug Metaboism and Disposition 2008; 36: 1679-1688.
3. Bhatt J, Shah B, Kambli S, Subbaiah G, Singh S and Ameta S. Rapid and sensitive method for the determination of sibutramine active metabolites in human plasma by reversed-phase liquid chromatography-tandem mass spectroscopy. Journal of Chromatographic Science 2007; 45: 91-96.
4. Chen J, Lu W, Zhang Q and Jiang X. Determination of the active metabolite of sibutramine by liquid chromatography-electrospray ionization tandem mass spectrometry. Journal of Chromatogrphy B: Analytical Technology in Biomedicine and Life Sciences 2003; 785: 197-203.
5. Chung JY, Jang SB, Lee YJ, Park MS and Park K. Effect of CYP2B6 Genotype on the pharmacokinetics of sibutramine and active metabolites in healthy subjects. Journal of Clinical Pharmacology 2010, doi: 10.1177/0091270010362906.
6. Connoley IP, Liu YL, Frost I, Reckless IP, Heal DJ and Stock MJ. Thermogenic effects of sibutramine and its metabolites. British Journal of Pharmacology 1999; 126: 1487-1495.
7. Ding L, Hao X, Huang X and Zhang S. Simultaneous determination of sibutramine and its N-desmethyl metabolites in human plasma by liquid chromatography-electrospray ionization-mass spectrometry: method and clinical applications. Analytical Chimica Acta 2003; 492: 241-248.
8. FDA. 2009 Sibutramine label information. Abbott Laboratories, North Chicago, IL. Available from:.
9. Hind ID, Mangham JE, Ghani SP, Haddock RE, Garratt CJ and Jones RW. Sibutramine pharmacokinetics in young and elderly healthy subjects. European Journal of Clinical Pharmacology 1999; 54: 847-849.
10. Jain DS, Subbaiah G, Sanyal M, Shrivastav PS, Pal U, Ghataliya S, Kakad A, Patel H and Shah S. Liquid chromatography/electrospray ionization tandem mass spectrometry validated method for the simultaneous quantification of sibutramine and its primary and secondary amine metabolites in human plasma and its application to a bioequivalence study. Rapid Communication in Mass Spectrometry 2006; 20: 3509-3521.
11. Kim KA, Song WK and Park JY. Association of CYP2B6, CYP3A5, and CYP2C19 genetic polymorphisms with sibutramine pharmacokinetics in healthy Korean subjects. Clinical Pharmacology and Therapeutics 2009; 86: 511-518.
12. Matuszewski BK, Constanzer ML and Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Analytical Chemistry 2003; 75: 3019-3030.
13. Nirogi RVS, Kandikere V, Shukla M, Mudigonda K and Maurya S. Sensitive and reproducible liquid chromatography-tandem mass spectrometry method for quantification of sibutramine in human plasma. Forensic Toxicology 2007; 25: 30-36.
14. Park JY, Kim KA, Park PW, Suh KH and Lee GS. Relative bioavailability and pharmacokinetics of a new sibutramine formulation in healthy male subjects: a randomized, open-label, two-period, comparative crossover study. Clinical Therapeutics 2004; 26: 2092-2101.
15. Stokvis E, Rosing H and Beijnen JH. Stable isotopically labeled internal standards in quantitative bioanalysis using liquid chromatography/mass spectrometry: necessity or not? Rapid Communication in Mass Spectrometry 2005; 19: 401-407.
16. Viswanathan CT, Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad JJ, Shah VP, Skelly JP, Swann PG and Weiner R. Quantitative bioanalytical methods validation and implementation: best practices for chromatographic and ligand binding assays. Pharmaceutical Research 2007; 24: 1962-1973.
17. Wu ST, Schoener D and Jemal M. Plasma phospholipids implicated in the matrix effect observed in liquid chromatography/tandem mass spectrometry bioanalysis: evaluation of the use of colloidal silica in combination with divalent or trivalent cations for the selective removal of phospholipids from plasma. Rapid Communication in Mass Spectrometry 2008; 22: 2873-2881.
18. Zhou SF, Liu JP and Chowbay B. Polymorphism of human cytochrome P450 enzymes and its clinical impact. Drug Metabolism Reviews 2009; 41: 89-295.